Postmenopausal Women Have Higher Risk for Developing Rheumatoid Arthritis
By Lori Solomon HealthDay Reporter
WEDNESDAY, Dec. 18, 2024 -- Postmenopausal women, particularly those who experience early menopause, may have a higher risk for developing rheumatoid arthritis (RA), according to a review published online Sept. 30 in BMC Rheumatology.
Negin Namavari, M.D., from the School of Medicine at Peymaniye Hospital and the Jahrom University of Medical Science in Iran, and colleagues conducted a systematic literature review and meta-analysis to assess the association between menopause and RA. Eleven studies were included in the meta-analysis.
The researchers found that postmenopausal women had a higher risk for developing RA versus premenopausal women (odds ratio, 1.35). Women who experienced early menopause (before 45 years of age) showed significantly higher odds of developing RA than those who underwent menopause at a normal age (odds ratio, 2.97).
"These findings underscore the importance of menopausal status as a potential risk factor for RA, with the substantial increase in RA risk associated with early menopause warranting particular attention from both clinicians and researchers," the authors write. "Our results suggest several avenues for future research, including investigation into the biological mechanisms underlying the association between menopause and RA risk, development of targeted preventive strategies for postmenopausal women (especially those who experience early menopause), and exploration of potential interventions to mitigate RA risk in these higher-risk groups."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-12-19 06:00
Read more
- Blood Test Might Alert Doctors to Problem Drinking
- High Cardiorespiratory Fitness Linked to Lower Dementia Risk
- Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007
- 2021 to 2022 Saw Decline in Abortions in the United States
- FDA Revokes EUA for REGEN-COV (casirivimab and imdevimab) for the Treatment of COVID-19
- FDA Approves Rapiblyk (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions